Exploring the Potential of CAR-T Therapy in ALL and Lymphomas

Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been made in recent years to improve treatment options for patients. Novel immunotherapies, such as chimeric antigen receptor T-cell (CAR-T) therapy and antibodies, are continuously being explored and have greatly changed the treatment landscape.

In this exclusive podcast, you will hear from experts Noelle Frey, MD, MSCE, University of Pennsylvania, Philadelphia, PA, Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, and Shannon Maude, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, who discuss the future of CAR-T therapy in ALL, highlighting the impact of the approval of tisagenlecleucel in adult patients, the promise of allogeneic products, and more. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

The post The future of CAR-T therapy in ALL appeared first on VJHemOnc.